We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Pomalidomide is active in the treatment of anemia associated with myelofibrosis.
- Authors
Tefferi, Ayalew; Verstovsek, Srdan; Barosi, Giovanni; Passamonti, Francesco; Roboz, Gail J; Gisslinger, Heinz; Paquette, Ronald L; Cervantes, Francisco; Rivera, Candido E; Deeg, H Joachim; Thiele, Juergen; Kvasnicka, Hans M; Vardiman, James W; Zhang, Yanming; Bekele, B Nebiyou; Mesa, Ruben A; Gale, Robert P; Kantarjian, Hagop M
- Abstract
Thalidomide and lenalidomide can alleviate anemia in myelofibrosis. However, their value is undermined by their respective potential to cause peripheral neuropathy and myelosuppression. We therefore evaluated the safety and therapeutic activity of another immunomodulatory drug, pomalidomide.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Vol 27, Issue 27, p4563
- ISSN
1527-7755
- Publication type
Journal Article
- DOI
10.1200/JCO.2008.21.7356